Dr. Alex Tatem on Retatrutide: A Physician's Breakdown Fact-Checked

Board-certified urologist Dr. Alex Tatem published a comprehensive video titled "Doctor Explains Retatrutide: The Most Powerful GLP-1 Weight Loss Drug Yet" covering the mechanism of action, Phase 2 trial data, comparison to semaglutide and tirzepatide, side effects, and FDA approval timeline. As a fellowship-trained physician and men's health specialist, Tatem brings medical credibility to the discussion — though his specialty is urology, not endocrinology or obesity medicine.

This page fact-checks his key claims against published data. Tatem does not recommend grey market retatrutide and explicitly warns against unregulated sourcing.

The Triple Agonist Mechanism: Accurate

Tatem provides a clear explanation of the three receptors retatrutide targets and what each does:

"Retatrutide enters the chat as the world's first triple agonist GLP-1 drug targeting GLP-1, GIP, and the glucagon receptor itself... This burn-a-bit-more component is likely why we see a steeper early weight loss curve with retatrutide compared to its competition."

— Dr. Alex Tatem

His mechanism explanation is accurate. The GLP-1 receptor drives appetite suppression and slows gastric emptying. GIP amplifies the insulin response and enhances satiety. The glucagon receptor component increases energy expenditure and fat oxidation — which is the key differentiator from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP).

His observation about beta-hydroxybutyrate levels increasing with high-dose retatrutide — indicating increased fatty acid oxidation — is also supported by Phase 2 substudies examining fatty liver outcomes.

For the full mechanism explanation, see What Is Retatrutide. For the fatty liver data, see Retatrutide and Fatty Liver.

Phase 2 Weight Loss Data: Accurate

Tatem cites specific Phase 2 numbers:

"Patients on 8 milligrams a week experienced a mean weight change of 22.8% and patients on 12 milligrams experienced a 24.2% reduction."

— Dr. Alex Tatem

Claim	Published NEJM Data	Verdict
8mg: 22.8% weight loss at 48 weeks	-22.8% (pooled 8mg group)	Accurate
12mg: 24.2% reduction at 48 weeks	-24.2% at 12mg	Accurate
100% of max-dose patients lost at least 5%	100% at 12mg lost ≥5%	Accurate
93% lost at least 10%	93% at 12mg lost ≥10%	Accurate
83% lost over 15%	83% at 12mg lost ≥15%	Accurate
By 24 weeks: 17.3–17.5% loss at top doses	~17% at 24 weeks for 8–12mg groups	Accurate

Tatem's Phase 2 data citations are precise and match the published New England Journal of Medicine paper. He correctly notes the rapid early weight loss — 17% by 24 weeks — which distinguishes retatrutide from slower-acting GLP-1 drugs.

For the full trial data, see Retatrutide Results.

Drug Comparisons: Accurate and Well-Contextualized

Tatem compares retatrutide's Phase 2 results to published data from semaglutide and tirzepatide:

Drug	His Claim	Published Data	Verdict
Semaglutide (STEP 1)	14.9% at 68 weeks (2.4mg dose)	14.9% at 68 weeks	Accurate
Tirzepatide 5mg (SURMOUNT-1)	15% at 72 weeks	15.0% at 72 weeks	Accurate
Tirzepatide 10mg	19.5% at 72 weeks	19.5% at 72 weeks	Accurate
Tirzepatide 15mg	20.9% at 72 weeks	20.9% at 72 weeks	Accurate
HbA1c reduction (retatrutide)	2 points at 24 weeks (12mg)	~2.0% at 12mg in Phase 2 T2D trial	Accurate

Importantly, Tatem adds appropriate caveats:

"There's no approved dose head-to-head readout yet in obesity, but there is a direct Phase 3 retatrutide versus tirzepatide trial that is ongoing today."

— Dr. Alex Tatem

This is a critical nuance that many content creators miss. Cross-trial comparisons (comparing Phase 2 retatrutide data to STEP 1 and SURMOUNT-1) are suggestive but not definitive — different trial populations, durations, and designs make direct comparisons imperfect. The ongoing head-to-head trial will provide definitive data.

For detailed comparisons, see Retatrutide vs Mounjaro.

Side Effects: Mostly Accurate

Tatem provides Phase 2 side effect data:

Side Effect	His Claim	Published Data	Verdict
Any adverse event (retatrutide)	82%	Ranged 73–82% across dose groups	Accurate (high end)
Any adverse event (placebo)	70%	~70%	Accurate
Serious adverse events	4%	4%	Accurate
Nausea	27%	Up to 25–27% at higher doses	Accurate
Diarrhea	13%	Up to 17% at some doses	Approximately accurate
Vomiting	10%	Up to 12%	Approximately accurate
Constipation	9%	Up to 12%	Approximately accurate
Cardiac arrhythmias	6% vs 3% placebo	Reported in Phase 2	Accurate
Pancreatitis	Under 1%	Under 1%	Accurate

His side effect presentation is solid. He correctly notes that most adverse events are GI-related and dose-dependent, typically occurring during dose escalation. The 82% figure represents the highest dose group — lower doses had lower rates. He also appropriately flags the cardiac arrhythmia signal (6% vs 3% placebo) and the heart rate increase that peaked at 24 weeks.

One thing he omits is the dysesthesia safety signal that emerged in TRIUMPH-4 Phase 3 data — a tingling/numbness sensation that was flagged as a new finding not seen in Phase 2.

For the full safety profile, see Retatrutide Side Effects.

FDA Timeline: Reasonable Estimates

Tatem discusses the approval timeline:

"The TRIUMPH study is looking to have its main obesity master protocol set for primary completion in May of 2026. This means the best case scenario for US approval is going to be 2027."

— Dr. Alex Tatem

He also mentions TRIUMPH Outcomes (cardiovascular/renal endpoints, 10,000 participants, estimated completion 2029) and the head-to-head trial against tirzepatide.

These timelines are consistent with publicly available ClinicalTrials.gov registrations. The 2027 earliest-approval estimate is shared by most analysts, though the actual timeline depends on when Eli Lilly files the NDA and the FDA's review speed.

For the latest timeline, see Retatrutide FDA Approval Timeline.

Grey Market Warning: Responsible

Tatem closes with a clear warning against grey market sourcing:

"We don't know what you're getting when you order these drugs from China or whatever supplier you have. Dosing can be inconsistent. And what's more concerning for me is the risk of heavy metal toxicity and other contaminants... I just cannot recommend it."

— Dr. Alex Tatem

This is a responsible stance. He acknowledges the reality that people are already using grey market retatrutide while clearly stating the risks — contamination, dosing inconsistency, and heavy metal toxicity. This is consistent with the FDA's warnings about non-approved GLP-1 products.

For more on this topic, see Grey Market Retatrutide.

Frequently Asked Questions

Who is Dr. Alex Tatem?

Dr. Alex Tatem is a board-certified, fellowship-trained urologist and men's health specialist. His practice focuses on low testosterone, erectile dysfunction, Peyronie's disease, male infertility, and performance enhancement. While he is a licensed physician, his specialty is urology — not endocrinology or obesity medicine. His retatrutide video is one of the more medically rigorous YouTube explainers available on the topic.

How accurate is Dr. Tatem's video?

Very accurate overall. His Phase 2 weight loss data, drug comparison numbers, side effect statistics, and mechanism explanation all match published sources. His main omission is the Phase 3 TRIUMPH-4 data (which may not have been published when he recorded), and he does not mention the dysesthesia safety signal from Phase 3. His FDA timeline estimates are reasonable and consistent with publicly available information.

No. Tatem explicitly does not recommend grey market retatrutide and warns against contamination and dosing inconsistency from unregulated suppliers. He presents the clinical data objectively and states that pharmaceutical-grade retatrutide is not yet available outside of clinical trials, with the earliest US approval expected in 2027.

Is retatrutide better than semaglutide and tirzepatide?

Based on the Phase 2 data Tatem cites, retatrutide produced greater percentage weight loss (24.2% at 48 weeks) than semaglutide (14.9% at 68 weeks) or tirzepatide (20.9% at 72 weeks). However, these are cross-trial comparisons with different populations and durations — not head-to-head results. A direct Phase 3 trial comparing retatrutide to tirzepatide is currently ongoing and will provide definitive data.

When will retatrutide be FDA approved?

Tatem estimates the best case is 2027, based on the TRIUMPH Phase 3 program's primary completion timeline of May 2026. This is consistent with analyst projections. After Phase 3 completion, Eli Lilly must file an NDA, and the FDA review process typically takes 10–12 months. The TRIUMPH Outcomes trial (cardiovascular/renal, 10,000 patients) is not expected to complete until 2029 but is not required for initial obesity approval.

Sources

Tatem, A. (2026). "Doctor Explains Retatrutide: The Most Powerful GLP-1 Weight Loss Drug Yet." YouTube. Watch on YouTube
Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
Eli Lilly and Company. (2025). TRIUMPH-4 results press release. Press release

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

Dr. Alex Tatem's video is educational content, not a personal medical recommendation. While he is a board-certified physician, his specialty is urology, not endocrinology or obesity medicine. His presentation of the clinical data is largely accurate but should not be taken as a substitute for consultation with an obesity medicine specialist.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Do not purchase or self-administer grey market peptides based on YouTube videos or any information on this site.

This site is not affiliated with Dr. Alex Tatem, Eli Lilly and Company, or any pharmaceutical manufacturer.

Sources